Novo Nordisk reported that oral semaglutide reduced the risk of major adverse cardiovascular events by 14% in adults with type 2 diabetes during the SOUL trial, which included 9,650 participants. The event occurred on October 21, 2024, with the company planning to seek regulatory approval for an expanded label in early 2025.